Calculating risk/benefit in X-linked severe combined immune deficiency disorder (X-SCID) Gene therapy trials: The task of ethical evaluation
Journal of Medicine and Philosophy 31 (5):533 – 564 (2006)
|Abstract||In response to adverse events in retroviral gene therapy clinical trials conducted in France to correct for X-linked severe combined immune deficiency disorder (X-SCID), an advisory committee of the Food and Drug Administration convened in October 2002, February 2003, and March 2005, to deliberate and provide recommendations for similarly sponsored research in the United States. A similar National Institutes of Health committee met in February 2003. In this article, I review the transcripts and/or minutes of these meetings to evaluate the extent to which the ethical dimension of the research was engaged even as the molecular and clinical evidence was reviewed. I then provide representative ethical arguments to demonstrate the sort of ethical reasoning that should be included as part of the agenda of such committee meetings.|
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
|Through your library||Configure|
Similar books and articles
Jeremy Sugarman (2004). Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials. Science and Engineering Ethics 10 (1):29-35.
W. French Anderson (1985). Human Gene Therapy: Scientific and Ethical Considerations. Journal of Medicine and Philosophy 10 (3):275-292.
Maurie Markman (2004). The Research Misconception. International Journal of Applied Philosophy 18 (2):241-252.
Richard F. Kitchener (1991). The Ethical Foundations of Behavior Therapy. Ethics and Behavior 1 (4):221 – 238.
Gerd Richter & Matthew D. Bacchetta (1998). Interventions in the Human Genome: Some Moral and Ethical Considerations. Journal of Medicine and Philosophy 23 (3):303 – 317.
Celia B. Fisher, Susan Z. Kornetsky & Ernest D. Prentice (2007). Determining Risk in Pediatric Research with No Prospect of Direct Benefit: Time for a National Consensus on the Interpretation of Federal Regulations. American Journal of Bioethics 7 (3):5 – 10.
Thomas C. Jones (2005). A Call to Restructure the Drug Development Process: Government Over-Regulation and Non-Innovative Late Stage (Phase III) Clinical Trials Are Major Obstacles to Advances in Health Care. Science and Engineering Ethics 11 (4):575-587.
Isaac Rabino (2003). Gene Therapy: Ethical Issues. Theoretical Medicine and Bioethics 24 (1):31-58.
John C. Fletcher (1985). Ethical Issues in and Beyond Prospective Clinical Trials of Human Gene Therapy. Journal of Medicine and Philosophy 10 (3):293-310.
Sorry, there are not enough data points to plot this chart.
Added to index2009-01-28
Total downloads1 ( #290,877 of 722,700 )
Recent downloads (6 months)0
How can I increase my downloads?